Previous 10 | Next 10 |
2023-11-08 08:48:36 ET More on Royalty Pharma Royalty Pharma: The Time Has Come Royalty Pharma: We Continue To Like The Strategy And Sell-Off Is Overdone Royalty Pharma Q3 2023 Earnings Preview Royalty Pharma to buy up to $1.5B of PTC Therapeutics’ roy...
Net cash provided by operating activities (GAAP) of $574 million and Adjusted Cash Receipts ( 1) (non-GAAP) of $637 million Announced transactions of up to $3.8 billion year-to-date, including $2.1 billion in upfront payments Raising 2023 guidance: Adjusted C...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Royalty Pharma plc (RPRX) is expected to report $0.81 for Q3 2023
2023-11-07 11:58:08 ET More on Royalty Pharma Royalty Pharma: The Time Has Come Royalty Pharma: We Continue To Like The Strategy And Sell-Off Is Overdone Royalty Pharma to buy up to $1.5B of PTC Therapeutics’ royalty on Evrysdi Royalty Pharma and Ferri...
2023-11-06 15:44:53 ET Summary The iShares U.S. Pharmaceuticals ETF provides targeted exposure to the U.S. pharmaceutical industry but has a highly concentrated portfolio. The IHE ETF's top five holdings, including Eli Lilly and Johnson & Johnson, account for over 63% of the f...
2023-10-19 19:02:30 ET A new royalty deal was the fuel that powered biotech PTC Therapeutics (NASDAQ: PTCT) stock to a 15% gain on Thursday. That arrangement, which covers PTC's spinal muscular atrophy (SMA) treatment Evrysdi, features a hefty upfront payment that could also bring i...
2023-10-19 08:10:21 ET More on Royalty Pharma Royalty Pharma: The Time Has Come Royalty Pharma: We Continue To Like The Strategy And Sell-Off Is Overdone Royalty Pharma and Ferring Pharmaceuticals enter $500M royalty agreement Seeking Alpha’s Quant Rat...
Royalty Pharma purchases a portion of royalties on Roche’s Evrysdi for $1.0 billion upfront PTC Therapeutics has option to sell rest of royalty for up to $500 million; Royalty Pharma has option to buy half of rest of royalty for up to $250 million Transaction expected to en...
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:0...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on September 13, 2024, to shareholders of record at the...